- Akston presented data from a randomized exploratory head-to-head study comparing AKS-548d and AKS-734 with bedinvetmab (Librela®) in dogs with radiographically confirmed osteoarthritis.
- Both investigational candidates produced clinically meaningful improvements in pain, function and orthopedic assessments that were generally consistent with those observed with bedinvetmab.
- The therapies induced sustained endogenous anti-NGF antibody responses and demonstrated functional neutralization of NGF-TrkA binding.
- A supplemental durability cohort showed detectable anti-NGF antibody responses through approximately 120 days following AKS-548d treatment.
- No treatment-related serious adverse events were reported.
- Akston plans to advance both candidates into blinded, placebo-controlled studies in client-owned dogs.
Akston Biosciences has reported encouraging early clinical data for two investigational immunotherapeutic candidates designed to treat canine osteoarthritis pain, with results suggesting efficacy comparable to Zoetis’ marketed anti-NGF therapy, Librela® (bedinvetmab).
Comparable improvements in pain and mobility
The findings were presented during the 2026 American College of Veterinary Internal Medicine (ACVIM) Forum and stem from a randomized exploratory study evaluating AKS-548d and AKS-734 in dogs with radiographically confirmed osteoarthritis and clinical signs of pain.
According to the company, both investigational therapies produced sustained reductions in modified Canine Brief Pain Inventory pain scores through Day 56 while improving functional mobility and orthopedic assessment scores. Although the study was not statistically powered to demonstrate efficacy, the observed clinical responses were generally consistent with those seen in dogs receiving bedinvetmab.
Immune-based approach may extend dosing interval
Unlike monoclonal antibody therapies that require repeated administration, Akston’s Ambifect® platform is designed to stimulate the animal’s own immune system to generate antibodies against nerve growth factor.
Both candidates generated sustained endogenous anti-NGF antibody responses that functionally neutralized NGF-TrkA binding. In an additional durability cohort, AKS-548d maintained detectable antibody responses through approximately four months, supporting future evaluation of extended dosing schedules, including potential twice-yearly administration.
Safety profile supports continued development
Akston reported no treatment-related serious adverse events during the study. The exploratory trial enrolled three treatment groups of five dogs and was designed primarily to evaluate safety, immunogenicity and pharmacologic activity. The company said both candidates will next be evaluated in blinded, placebo-controlled studies involving client-owned dogs with naturally occurring osteoarthritis.
Information sourced from the company’s press release.
